Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Telotristat Ethyl: First Global Approval.

Anthony Markham¹

¹Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

|April 7, 2017

Summary

Telotristat ethyl, a novel tryptophan hydroxylase inhibitor, effectively treats carcinoid syndrome diarrhea. This drug reduces serotonin production, offering a new therapeutic option for patients inadequately controlled by existing therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Daridorexant: First Approval.

Drugs·2022

Same author

Gefapixant: First Approval.

Drugs·2022

Same author

Daridorexant: First Approval.

Drugs·2022

Same author

Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.

Targeted oncology·2022

Same author

Envafolimab: First Approval.

Drugs·2022

Same author

Correction to: Avatrombopag: A Review in Thrombocytopenia.

Drugs·2021

Area of Science:

Pharmacology
Oncology
Endocrinology

Background:

Carcinoid syndrome, often caused by neuroendocrine tumors, leads to debilitating diarrhea due to excess serotonin (5-HT) secretion.
Current treatments for carcinoid syndrome diarrhea, such as somatostatin analogs (SSAs), may not provide adequate symptom control for all patients.

Purpose of the Study:

To summarize the key development milestones of telotristat ethyl, a peripheral tryptophan hydroxylase (TPH) inhibitor.
To highlight the regulatory pathway leading to the first global approval of telotristat ethyl for carcinoid syndrome diarrhea.

Main Methods:

Review of preclinical and clinical development data for telotristat ethyl.
Analysis of regulatory submissions and approvals in the United States.

Main Results:

Telotristat ethyl was developed as a TPH inhibitor to reduce serotonin production.
The drug demonstrated efficacy in treating carcinoid syndrome diarrhea when added to SSA therapy.

Conclusions:

Telotristat ethyl represents a significant advancement in managing carcinoid syndrome diarrhea.
The drug's approval marks a milestone in providing targeted therapy for this condition.

Related Experiment Videos